Neuralstem, Inc.’s (NASDAQ: CUR) patented technology enables the commercial-scale production of multiple types of central nervous system (CNS) stem cells, which are being developed as potential therapies for many CNS diseases and conditions. The company has completed phase Ia and Ib trials of NSI-189 for the treatment of major depressive disorder (MDD), and expects to initiate a phase II study next year. Neuralstem’s first stem cell product candidate, NSI-566, is under development for treatment of amyotrophic lateral sclerosis (ALS); in a phase 1 study to treat paralysis due to chronic spinal cord injury; and in a phase 1 study to treat paralysis from ischemic stroke. Its next generation stem cell product, NSI-532.IGF, is currently in early investigation for Alzheimer’s disease (AD). For more information, visit the company’s website at www.neuralstem.com